The WSJ Health Blog reports that Centers for Medicare and Medicaid Services (CMS) has decided there is not enough scientific evidence for Medicare to pay for genetic testing to customize Warfarin dosing.
CMS proposes paying for more research, and the New York Times story questions the cost effectiveness of a prospective study; but as we reported in February, NIGMS is already working on a prospective study that Frank Torti boosted at the time.
2 responses so far ↓
Trends Update — Personalized Medicine: DxS’ Latest Companion Diagnostics Deal « The Cross-Border Biotech Blog // May 31, 2009 at 1:32 pm |
[...] As personalized medicine inches toward becoming the standard of care for cancer, the question of who pays for the genotyping becomes more important. A deal announced Friday between DxS, a molecular diagnostics company, [...]
Biotech Trends Update: Costs Savings from Personalized Medicine Sought by PBMs, Employers, Pharma Face Legal and Privacy Hurdles « The Cross-Border Biotech Blog // February 4, 2010 at 1:22 pm |
[...] a neutral funding source for comparative effectiveness and personalized medicine research (despite also being a payor). This is a problem much bigger than just personalized medicine, but until trust is restored, [...]